Skip to main content

寡核苷酸 API 生产

加快从临床到上市的进程

与经验丰富的合同开发和生产组织安捷伦合作,确保您的临床和商业寡核苷酸 API 满足适当的质量标准、质量和纯度要求。

在美国科罗拉多州的两个前沿 cGMP 工厂中,安捷伦生产从克级到千克级的 siRNA、反义寡核苷酸、适配体、gRNA 和其他寡核苷酸。我们正在扩大产能,以承担更多项目、增加批量规模并更快地满足合作伙伴的需求。

安捷伦支持六个商业项目;您可以在整个临床试验和商业化过程中信赖我们的技术专长。与安捷伦一起,加快用于临床研究和上市的速度、扩大化学工艺规模、生产高质量的寡核苷酸 API。
Contact Us
+1 866-744-7638

改进方法

产品

|
|

按字母顺序排序

筛选
过滤器内容选择工具

需要帮助吗?使用选择工具找到产品。

精选资料

Accelerate Your Journey from Clinic to Market

Produce high-quality oligo APIs and efficiently advance from clinic to market, delivering therapeutics to patients with unmet medical needs

Agilent ClinGuide CRISPR sgRNA for Human Therapeutics

Accelerate the clinical success of therapeutic gene editing programs.

精选视频
返回页首
精选新闻

Colorado Governor Polis Helps Agilent Break Ground on $725 Million Expansion of Manufacturing Operations in Frederick

Agilent leaders joined Colorado Governor Jared Polis and local government officials to break ground on $725 million investment to double manufacturing capacity of therapeutic nucleic acids in Frederick, Colorado. The investment will create more than 160 life science jobs in the area. Agilent’s manufacturing facilities in Colorado produce siRNA, antisense molecules, and CRISPR guide RNA molecules.

Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics

Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.

0 选择的 COUNT_HERE 产品.

全部清除